We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
+15.9%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$4.81B
AUM Growth
+$276M
Cap. Flow
-$211M
Cap. Flow %
-4.39%
Top 10 Hldgs %
49.94%
Holding
159
New
17
Increased
40
Reduced
75
Closed
11

Top Buys

Rank Stock Value
1
RNAM
Avidity Biosciences
RNAM
+$87M
2
RVMD icon
Revolution Medicines
RVMD
+$38.9M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$26.8M
4
AKRO
Akero Therapeutics
AKRO
+$19.6M
5
IMCR icon
Immunocore
IMCR
+$12.1M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$93.6M
2
IONS icon
Ionis Pharmaceuticals
IONS
+$78.5M
3
BPMC
Blueprint Medicines
BPMC
+$36.5M
4
MRNA icon
Moderna
MRNA
+$34.3M
5
SYK icon
Stryker
SYK
+$32.5M

Sector Composition

Rank Sector Weight
1 Healthcare 99.85%
2 Technology 0.03%
3 Consumer Discretionary 0.02%
4 Communication Services 0.02%
5 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PTGX icon
101
Protagonist Therapeutics
PTGX
$8.91B
$1.37M 0.03%
20,581
+1,109
+6% +$63K
AVTR icon
102
Avantor
AVTR
$7.35B
$1.29M 0.03%
+103,362
New +$1.33M
BBNX
103
Beta Bionics
BBNX
$774M
$1.28M 0.03%
64,283
-2,542
-4% -$44.7K
UTHR icon
104
United Therapeutics
UTHR
$22.6B
$1.11M 0.02%
+2,640
New +$888K
MDGL icon
105
Madrigal Pharmaceuticals
MDGL
$12.4B
$1.1M 0.02%
2,393
+1,293
+118% +$482K
BBIO icon
106
BridgeBio Pharma
BBIO
$15.9B
$1.06M 0.02%
20,356
+9,956
+96% +$486K
MLYS icon
107
Mineralys Therapeutics
MLYS
$2.36B
$1.01M 0.02%
26,605
+11,049
+71% +$239K
RYTM icon
108
Rhythm Pharmaceuticals
RYTM
$7.27B
$914K 0.02%
9,053
-11,853
-57% -$1.1M
BKD icon
109
Brookdale Senior Living
BKD
$3.56B
$887K 0.02%
+104,665
New +$798K
CERT icon
110
Certara
CERT
$1.09B
$726K 0.02%
59,447
-22,293
-27% -$244K
DOCS icon
111
Doximity
DOCS
$3.91B
$709K 0.01%
9,693
-14,123
-59% -$921K
BIIB icon
112
Biogen
BIIB
$30B
$590K 0.01%
4,213
+3,811
+948% +$515K
IWM icon
113
iShares Russell 2000 ETF
IWM
$81.8B
$557K 0.01%
2,300
– –
GRMN
114
Garmin
GRMN
$47.5B
$500K 0.01%
2,031
+1,181
+139% +$273K
RPRX icon
115
Royalty Pharma
RPRX
$25.8B
$457K 0.01%
+12,961
New +$469K
PLNT icon
116
Planet Fitness
PLNT
$4.34B
$446K 0.01%
4,301
+1,601
+59% +$170K
SNY icon
117
Sanofi
SNY
$106B
$418K 0.01%
+8,860
New +$428K
NAMS icon
118
NewAmsterdam Pharma
NAMS
$3.61B
$416K 0.01%
14,611
-5,944
-29% -$142K
AAPL icon
119
Apple
AAPL
$4.78T
$410K 0.01%
+1,609
New +$363K
TEM
120
Tempus AI
TEM
$8.62B
$405K 0.01%
5,013
+4,776
+2,015% +$334K
AMZN icon
121
Amazon
AMZN
$2.71T
$398K 0.01%
1,812
+662
+58% +$150K
SMMT icon
122
Summit Therapeutics
SMMT
$10.8B
$392K 0.01%
18,982
-22,756
-55% -$552K
EXEL icon
123
Exelixis
EXEL
$14.2B
$304K 0.01%
7,361
-1,139
-13% -$45.8K
PFE icon
124
Pfizer
PFE
$142B
$301K 0.01%
11,827
-59,088
-83% -$1.46M
META icon
125
Meta Platforms (Facebook)
META
$1.64T
$294K 0.01%
+400
New +$298K
3 4
5
6 7

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2025 Portfolio in Review

As of Q3 2025, Bellevue Group held 159 positions worth $4.81B, up 6.1% from $4.54B the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Bellevue Group withdrew a net $211M in Q3 2025, closing 11 positions and reducing 75 holdings. Its most notable exit was Blueprint Medicines, an estimated $36.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Bellevue Group opened a new position in Avidity Biosciences worth $93.8M.

  • Bellevue Group's largest Q3 2025 buy was Avidity Biosciences: 2,152,862 shares worth $93.8M.
  • Bellevue Group added most to Revolution Medicines in Q3 2025, an estimated $38.9M increase.
  • Bellevue Group's biggest Q3 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $93.6M.
  • Bellevue Group fully exited Blueprint Medicines in Q3 2025, selling an estimated $36.5M.
  • Bellevue Group's ten largest holdings make up 50% of its $4.81B portfolio in Q3 2025.
  • Bellevue Group opened 17 new positions and closed 11 in Q3 2025.
  • Bellevue Group's portfolio value rose 6.1% quarter-over-quarter to $4.81B.

Based on Bellevue Group's 13F filing for Q3 2025, filed 14 Nov 2025.